Literature DB >> 8471183

Marketing aspects of company-sponsored postmarketing surveillance studies.

M D Stephens.   

Abstract

Mesh:

Year:  1993        PMID: 8471183     DOI: 10.2165/00002018-199308010-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  6 in total

1.  Channeling bias in the interpretation of drug effects.

Authors:  H Petri; J Urquhart
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

2.  Review of company postmarketing surveillance studies.

Authors:  P C Waller; S M Wood; M J Langman; A M Breckenridge; M D Rawlins
Journal:  BMJ       Date:  1992-06-06

3.  Guidelines on postmarketing surveillance. Joint committee of ABPI, BMA, CSM, and RCGP.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-06

4.  Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods.

Authors:  A C Rossi; D E Knapp; C Anello; R T O'Neill; C F Graham; P S Mendelis; G R Stanley
Journal:  JAMA       Date:  1983 Apr 22-29       Impact factor: 56.272

5.  Postmarketing surveillance of adverse reactions to drugs.

Authors:  M D Rawlins
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-24

6.  W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.

Authors: 
Journal:  Lancet       Date:  1980-08-23       Impact factor: 79.321

  6 in total
  6 in total

1.  Physician rewards for postmarketing surveillance (seeding studies) in the US.

Authors:  J La Puma
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

2.  What is drug safety?: celebrating 20 years of the Drug Safety journal.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patients.

Authors:  J La Puma; C B Stocking; W D Rhoades; C M Darling; R E Ferner; J Neuberger; M VandenBurg; I Dews; J S Tobias
Journal:  BMJ       Date:  1995-06-24

4.  Promoting transparency in pharmaceutical industry-sponsored research.

Authors:  Joseph S Ross; Cary P Gross; Harlan M Krumholz
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

5.  International variation in prescribing antihypertensive drugs: its extent and possible explanations.

Authors:  Atle Fretheim; Andrew D Oxman
Journal:  BMC Health Serv Res       Date:  2005-03-11       Impact factor: 2.655

6.  Marketing trials, marketing tricks - how to spot them and how to stop them.

Authors:  Alastair Matheson
Journal:  Trials       Date:  2017-03-08       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.